Malignant tumors are the most important risk factor for venous thrombosis (VTE), and VTE has become the second leading cause of death for tumor patients. Studies have shown that the risk of VTE in cancer patients is at least 4 to 6 times higher than that in non-tumor patients, and VTE increases the likelihood of death in cancer patients by 2 to 6 times. In March 2021, the National Comprehensive Cancer Network (NCCN) issued guidelines to guide everyone to pay attention to the prevention and treatment of VTE in cancer patients.
◆Hospitalized tumor patients are high-risk groups of VTE.
◆It is recommended that all hospitalized patients diagnosed with active tumors or clinically suspected tumors without contraindications should be treated with preventive anticoagulation (Class 1 recommendation).
◆Class 1 recommended drugs for preventive anticoagulation therapy include: LMWH, Fondaparinux and UFH.
references：NCCN Clinical Practice Guidelines in Oncoligy：Cancer-Associated Venous Thromboembolic Disease（2021.V1）